Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

University of Pennsylvania logo

University of Pennsylvania

Status and phase

Enrolling
Phase 4

Conditions

Psoriasis

Treatments

Drug: Secukinumab Auto-Injector

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT04535999
834149

Details and patient eligibility

About

This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.

Full description

This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. This is a single arm trial - all patients will receive the study drug. We will examine time to response and different methods of defining nail disease response.

Enrollment

40 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Active psoriatic nail disease defined as a Minimum 4 or more fingernails OR NAPSI>20
  • Active skin psoriasis currently (no minimum PASI or BSA) or skin psoriasis in the past documented by a dermatologist
  • Age 18-85

Exclusion criteria

  • History of IL-17 inhibitor use (other therapies including TNF inhibitors or non- biologics DMARDS in the past are acceptable)
  • Inflammatory bowel disease
  • Metal implants or other concerns for use of MRI
  • Active infection
  • Patients may have a history of self-reported psoriatic arthritis but may not have active PsA at the time of screening.
  • We will exclude patients with onychomyosis of the fingernails on clippings

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

40 participants in 1 patient group

Open Label
Experimental group
Description:
Secukinumab
Treatment:
Drug: Secukinumab Auto-Injector

Trial contacts and locations

1

Loading...

Central trial contact

Sarah Gillespie, MS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems